These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 29441189)

  • 41. Neuroleptic malignant syndrome in a patient on long-term olanzapine treatment at a stable dose: Successful treatment with dantrolene.
    Kouparanis A; Bozikas A; Spilioti M; Tziomalos K
    Brain Inj; 2015; 29(5):658-60. PubMed ID: 25625410
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Electroconvulsive Therapy in the Neuroleptic Malignant Syndrome.
    Casey DA
    Convuls Ther; 1987; 3(4):278-283. PubMed ID: 11940929
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Catatonia and neuroleptic malignant syndrome: two disorders on a same spectrum? Three case reports].
    Luchini F; Lattanzi L; Bartolommei N; Cosentino L; Casamassima F; Litta A; Mauri M; Cassano GB
    Riv Psichiatr; 2012; 47(2):178-85. PubMed ID: 22622253
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Clozapine-associated neuroleptic malignant syndrome followed by catatonia: a case report].
    Erol A; Putgül G; Sert E; Mete L
    Turk Psikiyatri Derg; 2013; 24(2):140-4. PubMed ID: 23754268
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Neuroleptic Malignant Syndrome: A Case Aimed at Raising Clinical Awareness.
    Al Danaf J; Madara J; Dietsche C
    Case Rep Med; 2015; 2015():769576. PubMed ID: 26170837
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Neuroleptic malignant syndrome due to risperidone misdiagnosed as status epilepticus.
    Arslankoylu AE; Kutuk MO; Okuyaz C; Toros F
    Pediatr Rep; 2011 Jun; 3(3):e19. PubMed ID: 22053263
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The influence of concomitant neuroleptic medication on safety, tolerability and clinical effectiveness of electroconvulsive therapy.
    Nothdurfter C; Eser D; Schüle C; Zwanzger P; Marcuse A; Noack I; Möller HJ; Rupprecht R; Baghai TC
    World J Biol Psychiatry; 2006; 7(3):162-70. PubMed ID: 16861142
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Detection and management of the neuroleptic malignant syndrome.
    Bond WS
    Clin Pharm; 1984; 3(3):302-7. PubMed ID: 6145537
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Development of Neuroleptic Malignant Syndrome in a Patient with Lewy Body Dementia after Intramuscular Administration of Paliperidone.
    Yeung HM; Schmitz S; Kvantaliani N; Martin C
    Case Rep Neurol Med; 2021; 2021():8879333. PubMed ID: 33520321
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Carbamazepine in the treatment of neuroleptic malignant syndrome.
    Thomas P; Maron M; Rascle C; Cottencin O; Vaiva G; Goudemand M
    Biol Psychiatry; 1998 Feb; 43(4):303-5. PubMed ID: 9513741
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Neuroleptic malignant syndrome.
    Rampertaap MP
    South Med J; 1986 Mar; 79(3):331-6. PubMed ID: 3513330
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Electroconvulsion therapy for neuroleptic malignant syndrome].
    Buggenhout S; Vandenberghe J; Sienaert P
    Tijdschr Psychiatr; 2014; 56(9):612-5. PubMed ID: 25222100
    [TBL] [Abstract][Full Text] [Related]  

  • 53. ECT as a treatment alternative for patients with symptoms of neuroleptic malignant syndrome.
    Addonizio G; Susman VL
    J Clin Psychiatry; 1987 Mar; 48(3):102-5. PubMed ID: 2880837
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Spontaneous seizures after ECT in a patient medicated with bupropion, sertraline and risperidone.
    Doellinger OV; Ribeiro JP; Ribeiro Â; Freitas C; Ribeiro B; Silva JC
    Trends Psychiatry Psychother; 2016 Jun; 0():0. PubMed ID: 27355895
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Toxic serotonin syndrome or neuroleptic malignant syndrome?
    Fink M
    Pharmacopsychiatry; 1996 Jul; 29(4):159-61. PubMed ID: 8858716
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Neuroleptic malignant syndrome: a life-threatening complication that can be treated effectively].
    van Waarde JA; Muller ME; Verweg B
    Ned Tijdschr Geneeskd; 2006 Nov; 150(46):2517-20. PubMed ID: 17152323
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Multiple ECT late in the course of neuroleptic malignant syndrome.
    McKinney P; Kellner C
    Convuls Ther; 1997 Dec; 13(4):269-73. PubMed ID: 9437570
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Residual catatonic state following neuroleptic malignant syndrome.
    Caroff SN; Mann SC; Keck PE; Francis A
    J Clin Psychopharmacol; 2000 Apr; 20(2):257-9. PubMed ID: 10770467
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Neuroleptic malignant syndrome with delayed onset of fever following risperidone administration.
    Norris B; Angeles V; Eisenstein R; Seale JP
    Ann Pharmacother; 2006 Dec; 40(12):2260-4. PubMed ID: 17119106
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Electroconvulsive Therapy of the Lethal Catatonia Syndrome.
    Mann SC; Caroff SN; Bleier HR; Antelo RE; Un H
    Convuls Ther; 1990; 6(3):239-247. PubMed ID: 11941074
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.